SAB BIO to Present Groundbreaking Diabetes Treatment
MIAMI – SAB BIO (Nasdaq: SABS), a leading clinical-stage biopharmaceutical company, is making strides in developing an innovative immunotherapy for type 1 diabetes (T1D). This promising treatment utilizes a human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or slowing the progression of this complex condition.
Presentation at the EASD Annual Meeting
On September 9, 2024, SAB BIO will showcase its work at the significant 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid. The session, led by Alexandra Kropotova, MD, MBA, who is the Executive Vice President and Chief Medical Officer at SAB, will feature a pivotal presentation titled “Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142.” This presentation will provide essential insights into their advanced immunotherapy strategy.
Event Details
The EASD Annual Meeting, taking place in the Beijing Hall during the INNODIA EASD Symposium at 8:45 am, is one of the foremost global gatherings focused on diabetes research and treatment. It draws thousands of delegates, including experts who come together to explore the latest advancements and possibilities in diabetes care.
What is SAB-142?
SAB-142 represents a cutting-edge therapeutic option designed to serve as a human equivalent to rabbit anti-thymocyte globulin (ATG). This innovative treatment departs from traditional models by employing a low dosage of a human antibody, which significantly reduces the risk of severe immune reactions compared to its rabbit-derived counterpart. Clinical studies have shown that a single modest dose of rabbit ATG can effectively modulate the immune response, slowing the damaging progression of T1D by preserving the function of pancreatic beta cells.
How Does It Work?
The action of SAB-142 targets the immune cells that attack insulin-producing beta cells. By intervening at this critical point, the therapy aims to protect the body's ability to produce insulin, a vital hormone for regulating blood sugar levels. Unlike rabbit ATG, which can lead to serum sickness and immune responses like the production of anti-drug antibodies, SAB-142's human-derived antibodies strive for safer and more consistent treatment over time, which can enhance patient compliance and improve therapy outcomes.
About SAB BIO
SAB BIO is at the forefront of advancements in the biopharmaceutical field, committed to addressing significant unmet medical needs in immune and autoimmune disorders. By employing innovative genetic engineering techniques to develop their Transchromosomic (Tc) Bovine™ platform alongside the DiversitAb™ drug development system, SAB BIO is uniquely positioned to produce a diverse range of multi-targeted, high-potency immunoglobulins (IgGs). This groundbreaking production model eliminates the historical reliance on human donors or convalescent plasma, paving the way for new treatment possibilities for conditions like T1D.
Contacts
For media inquiries, please reach out to: Media Relations:
khollon@sab.bio
For investor relations, please contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What is SAB-142?
SAB-142 is a human immunotherapy designed to protect pancreatic beta cells, helping to delay the progression of type 1 diabetes.
When will SAB BIO present at the EASD Annual Meeting?
SAB BIO is set to present on September 9, 2024, during the INNODIA EASD Symposium in Madrid.
Who is leading the presentation at EASD?
The presentation will be led by Dr. Alexandra Kropotova, who serves as the Executive Vice President and Chief Medical Officer of SAB BIO.
How does SAB-142 differ from rabbit ATG?
SAB-142 is human-derived, which minimizes the risk of allergic reactions and allows for safer re-dosing compared to rabbit ATG, which can provoke severe immune responses.
How is SAB BIO addressing treatment for T1D?
SAB BIO is developing innovative treatments that utilize advanced technologies to target and preserve insulin-producing cells, fundamentally transforming the management of type 1 diabetes.
